Tocqueville Asset Management L.P. Acquires Shares of 71,878 United Therapeutics Corporation $UTHR

Tocqueville Asset Management L.P. bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, Holdings Channel reports. The firm bought 71,878 shares of the biotechnology company’s stock, valued at approximately $38,946,000.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. Torren Management LLC bought a new position in shares of United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics in the fourth quarter valued at about $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 2.1%

Shares of United Therapeutics stock opened at $529.14 on Thursday. The stock’s fifty day simple moving average is $534.23 and its 200 day simple moving average is $537.17. The company has a market capitalization of $22.69 billion, a PE ratio of 18.93, a PEG ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the previous year, the firm earned $6.41 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. Analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,185,323.93. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 434,275 shares of company stock worth $235,371,678 in the last quarter. 8.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent analyst reports. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.